SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, a member of the Roche Group (RHHBY.PK), Sunday announced results from a Phase III trial, ASTERIA II, which demonstrated that omalizumab met its primary endpoint in patients with moderate to severe chronic idiopathic urticaria, who remained symptomatic despite treatment with approved H1 antihistamine doses1.
Chronic idiopathic urticaria is a skin condition characterized by red, swollen, itchy hives on the skin and is diagnosed when hives spontaneously present and reoccur for more than six weeks.
Genentech plans to file a supplemental biologics license application with the U.S. Food and Drug Administration for omalizumab in chronic idiopathic urticaria later this year.
Copyright(c) 2013 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2013 AFX News
